JP2009539845A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539845A5
JP2009539845A5 JP2009514365A JP2009514365A JP2009539845A5 JP 2009539845 A5 JP2009539845 A5 JP 2009539845A5 JP 2009514365 A JP2009514365 A JP 2009514365A JP 2009514365 A JP2009514365 A JP 2009514365A JP 2009539845 A5 JP2009539845 A5 JP 2009539845A5
Authority
JP
Japan
Prior art keywords
cmv
pul128
pul130
protein
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009514365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539845A (ja
JP5822433B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013365 external-priority patent/WO2007146024A2/en
Publication of JP2009539845A publication Critical patent/JP2009539845A/ja
Publication of JP2009539845A5 publication Critical patent/JP2009539845A5/ja
Application granted granted Critical
Publication of JP5822433B2 publication Critical patent/JP5822433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009514365A 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Active JP5822433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20
PCT/US2007/013365 WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013154361A Division JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Publications (3)

Publication Number Publication Date
JP2009539845A JP2009539845A (ja) 2009-11-19
JP2009539845A5 true JP2009539845A5 (https=) 2010-06-17
JP5822433B2 JP5822433B2 (ja) 2015-11-24

Family

ID=38832360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Country Status (5)

Country Link
US (5) US7704510B2 (https=)
EP (2) EP3031469B1 (https=)
JP (3) JP5822433B2 (https=)
CA (1) CA2654563A1 (https=)
WO (1) WO2007146024A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
EP2144627A1 (en) * 2007-05-11 2010-01-20 Vakzine Projekt Management GmbH Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202400B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
CA2878344A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CN110241137A (zh) * 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
CN109045294A (zh) * 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11524069B2 (en) * 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CN113271968B (zh) 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN115698298A (zh) * 2020-06-09 2023-02-03 Km生物医薬股份公司 巨细胞病毒的gB与五聚体的融合蛋白和包含该融合蛋白的疫苗
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4192494A4 (en) * 2020-08-06 2024-11-13 La Jolla Institute for Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US20040087001A1 (en) * 2001-02-21 2004-05-06 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2009539845A5 (https=)
US11129891B2 (en) Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CA2809780C (en) Influenza virus neutralizing antibody and method for screening same
CA3081694C (en) Monoclonal antibodies for ebola and marburg viruses
JP2013241442A5 (https=)
Thornlow et al. Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization
CN110294802B (zh) 一种单克隆抗体10g12及其应用
CN114478755A (zh) 抗新型冠状病毒的全人源抗体及其组合物与应用
TW202144405A (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
Wang et al. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA. 1-BA. 5
Stryjewska et al. Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy
WO2011137571A1 (zh) 人源抗狂犬病毒糖蛋白中和性抗体rvfab5
CN104220090A (zh) 肠道病毒71型的特异性抗体及其用途
CN105985433B (zh) 针对h7n9亚型禽流感病毒的全人源单克隆抗体及应用
de Carvalho Nicacio et al. Neutralizing human Fab fragments against measles virus recovered by phage display
CN114805570B (zh) 一种抗人ace2单克隆抗体及其应用
CN105481979A (zh) 人源抗狂犬病毒糖蛋白中和性抗体rv3a5及其应用
CN113583118A (zh) 用于检测番鸭呼肠孤病毒的单链抗体、嵌合抗体和双夹心elisa检测试剂盒
Liu et al. Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine
CN109212205B (zh) 伪狂犬病病毒gC蛋白抗体、含该抗体的试剂盒及应用
Zhang et al. A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection
Pastrana et al. Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid
CN117777280A (zh) 新型冠状病毒SARS-CoV-2广谱中和单域抗体及其应用
Gillet et al. Glycoprotein L sets the neutralization profile of murid herpesvirus 4
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途